Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir

Shin, Jüng Woo; Jeong, Joonho; Jung, Seok Won; Lee, Seung Bum; Park, Bo Ryung; Kim, Min-Ju; Park, Eun Ji; Park, Neung Hwa

doi:10.1007/s10620-020-06375-3

Cited by 18 publications

(38 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, neither the TC/HDL ratio nor the LDL/HDL ratio was different between groups. These results appear to be consistent with the explanation that TAF is lipid-neutral, as indicated in previous clinical trial [ 14 ]. It was speculated that the unique pharmacokinetics of TAF, which enables a high intracellular transfer compared with TDF and lowers plasma TFV concentration, may be a possible explanation.…”

Section: Discussionsupporting

confidence: 93%

“…They had general health check-up at the Health Screening and Promotion Center in Ulsan University Hospital. A total of 900 patients treated with TDF in our CHB cohort [ 14 ] were also involved in this study as another control group. The inclusion criteria in this study for TAF group were as follows: 1) patients who were ≥18 years old with chronic HBV infection, 2) patients who had not received interferon therapy prior to TAF therapy, 3) patients with an estimated creatinine clearance ≥15 mL/min (by the Cockcroft-Gault method), and 4) patients who received treatment with TAF therapy for ≥48 weeks.…”

Section: Methodsmentioning

confidence: 99%

“…Center in Ulsan University Hospital. A total of 900 patients treated with TDF in our CHB-cohort [14],…”

Section: This Was Carried Out As Part Of General Health Examination At the Health Screening And Promotionmentioning

confidence: 99%

See 2 more Smart Citations

Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background/Aims: Tenofovir alafenamide (TAF) has a less favorable effect on lipids compared to TDF (Tenofovir disoproxil fumarate) in clinical trials. However, data regarding these outcomes in patients with chronic hepatitis B (CHB) are scarce.Methods: This study is to evaluate the effects of TAF on the lipids of 237 CHB patients, compared with TDF, inactive CHB, and non-HBV infected control groups, using propensity score-matching (PSM).

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…2A). In the 21 studies [9][10][11][12][13][14][15][16][17][18][19][20]22,[24][25][26][27][28][45][46][47] reporting aHR, the pooled aHR was 0.81 (95% CI: 0.72-0.91) with significant heterogeneity (I 2 = 47%, P = 0.007) as well (Fig. 2b).…”

Section: Meta-analysismentioning

confidence: 99%

Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta‐analysis

Yuan

Huo

et al. 2022

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and Aim Previous smaller meta‐analyses comparing the incidence of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients treated with tenofovir disoproxil fumarate (TDF) versus entecavir (ETV) provided controversial results. This updated meta‐analysis aimed to reliably identify any difference in the HCC incidence between TDF‐treated or ETV‐treated CHB patients in general or in specific subgroups. Methods PubMed, EMBASE, Web of Science, and Cochrane Library were systematically searched for relevant studies with hazard ratios (HRs) for HCC between TDF‐treated and ETV‐treated CHB patients. Retrieved dates ranged from January 2009 to October 2021. HRs with or without adjustment were pooled with random‐effects model. Results Twenty‐four comparative studies involving 37 771 CHB patients treated with TDF and 72 094 treated with ETV were included. TDF was associated with lower risk of HCC compared with ETV, with pooled unadjusted HR of 0.76 (95% confidence interval [CI]: 0.67–0.86) (24 studies) and adjusted HR of 0.81 (95% CI: 0.72–0.91) (21 studies). In propensity score matching cohorts, the TDF superiority was confirmed for unadjusted HR 0.83 (95% CI: 0.71–0.97) (14 studies) and was close to significance for adjusted HR (0.78, 95% CI: 0.58–1.04) (8 studies). Subgroup analyses showed that TDF was associated with lower HCC risk than ETV treatment in CHB patients who were from Asia (adjusted HR: 0.76, 95% CI: 0.66–0.87; 15 studies) or nucleos(t)ide naïve (adjusted HR:0.74, 95% CI: 0.65–0.84; 18 studies). Conclusion Current evidence from a sizable population suggests that TDF is associated with significantly lower HCC risk compared with ETV treatment in patients who are from Asia and/or nucleos(t)ide naïve.

show abstract

“…Multivariate analysis showed that the risk of HCC and death or LT was statistically similar between ETV and TDF groups (aHR, 0.83; 95% CIs, 0.52–1.31; P =0.413 and aHR, 0.64; 95% CIs, 0.26–1.57; P =0.325, respectively) after adjusting for adherence to medication and maintained virologic response. In the 589 PSM patients, the risk of HCC and death or LT was also statistically similar between the two groups (aHR, 0.77; 95% CIs, 0.46–1.29; P =0.319 and aHR, 0.64; 95% CIs, 0.30–1.38; P =0.257, respectively) [ 15 ].…”

Section: Entecavir and Tenofovir Equally Prevents Hccmentioning

confidence: 99%

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

et al. 2021

View full text Add to dashboard Cite

Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediate-term efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development. a Data are presented as mean ± standard deviation. 4060 (100) 6145 (100) 16.9 18.1 49 (0.61) 41 (0.32)

show abstract

Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir

Cited by 18 publications

References 49 publications

Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis

Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis

Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta‐analysis

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

Contact Info

Product

Resources

About